Skip to main content

Table 2 Correlation of Cezanne protein expression with clinicopathological parameters

From: Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma

Characteristics No. of patients Cezanne expression (%) P -value
Low High
Gender     
  Female 26 10 (38.5%) 16 (61.5%) 0.103
  Male 204 113 (55.4%) 91 (44.6%)  
Age (years)     
  ≤50 118 62 (52.5%) 56 (47.5%) 0.826
  >50 112 61 (54.5%) 52 (45.5%)  
AFP (μg/l)     
  ≤20 82 44 (53.7%) 38 (46.3%) 0.967
  >20 148 79 (53.4%) 69 (46.6%)  
HBsAg     
  Negative 15 9 (60.0%) 6 (40.0%) 0.600
  Positive 215 114 (53.0%) 101 (47.0%)  
GGT (U/l)     
  ≤50 122 58 (47.5%) 64 (52.5%) 0.055
  >50 108 65 (60.2%) 43 (39.8%)  
Liver cirrhosis     
  No 50 26 (52.0%) 24 (48.0%) 0.813
  Yes 180 97 (53.9%) 83 (46.1%)  
Tumor size (cm)     
  ≤5 132 58 (43.9%) 74 (56.1%) 0.001
  >5 98 65 (66.3%) 33 (33.7%)  
Tumor number*     
  Single 213 113 (53.1%) 100 (46.9%) 0.646
  Multiple 17 10 (58.8%) 7 (41.2%)  
Satellite nodule     
  No 199 98 (49.2%) 101 (50.8%) 0.001
  Yes 31 25 (80.6%) 6 (19.4%)  
Tumor capsule     
  No/incomplete 141 77 (54.6%) 64 (45.4%) 0.665
  Complete 89 46 (51.7%) 43 (48.3%)  
Tumor differentiation     
  I-II 157 88 (56.1%) 69 (43.9%) 0.251
  III-IV 73 35 (47.9%) 38 (52.1%)  
Vascular invasion     
  No 207 105 (50.7%) 102 (49.3%) 0.012
  Yes 23 18 (78.3%) 5 (21.7%)  
TNM stage     
  I 178 88 (49.4%) 90 (50.6%) 0.020
  II 11 5 (45.5%) 6 (54.5%)  
  III 41 30 (73.2%) 11 (26.8%)  
BCLC stage     
  0 20 4 (20.0%) 16 (80.0%) 0.001
  A 106 52 (49.1%) 54 (50.9%)  
  B 80 49 (61.3%) 31 (38.7%)  
  C 24 18 (75.0%) 6 (25.0%)  
Early recurrence     
  No 145 56 (38.6%) 89 (61.4%) <0.001
  Yes 85 67 (78.8%) 18 (21.2%)  
MMP-9 expression     
  Low 118 51 (43.2%) 67 (56.8%) 0.001
  High 112 72 (64.3%) 40 (35.7%)  
  1. *Tumor number indicates number of primary tumor mass detected at the time of surgical operation.